A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

ClinicalTrials.gov ID: NCT06146257

Public ClinicalTrials.gov record NCT06146257. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 3, 2026, 10:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A First-in-human, Phase 1, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes

Study identification

NCT ID: NCT06146257
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: GluBio Therapeutics Inc.; Industry
Enrollment: 48 participants

Conditions and interventions

Conditions

Interventions

GLB-001 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 10, 2024
Primary completion: Jun 30, 2026
Completion: Oct 7, 2026
Last update posted: Apr 12, 2026

2024 – 2026

United States locations

U.S. sites: 8
U.S. states: 4
U.S. cities: 7

Facility	City	State	ZIP	Site status
City of Hope Medical Center	Duarte	California	91010	Recruiting
University of California Irvine	Irvine	California	92697	Terminated
University of Kansas Medical Center Research Institute, Inc.	Kansas City	Kansas	66160	Recruiting
Alliance for Multispecialty Research, LLC	Merriam	Kansas	66204	Terminated
Roswell Park Comprehensive Cancer Center	Buffalo	New York	14263	Terminated
Memorial Sloan Kettering Cancer Center-David H. Koch Center	New York	New York	10021	Terminated
Icahn School of Medicine at Mount Sinai	New York	New York	10029	Recruiting
University of Texas M. D. Anderson Cancer Center	Houston	Texas	77030	Terminated

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06146257, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 12, 2026 · Synced May 3, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06146257 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →